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ACE inhibition prevents renal failure and death in uninephrectomized
MWFIZtm rats. Many studies have consistently documented that angio-
tensin converting enzyme (ACE) inhibitors prevent proteinuria and
glomeruloscierosis in progressive renal disease, but very few data are
available on whether they also prevent renal failure and death. The
mechanisms of the beneficial effect of ACE inhibition are only partially
understood. Recent data suggest that angiotensin II modulates renal
synthesis of endothelin-1, a vasoactive peptide implicated in the process of
renal injury. Here we investigated in a long-term study whether ACE
inhibition ameliorated renal function in uninephrectomized (UNx) male
MWF/Ztm rats. Three groups of rats at nine weeks of age underwent UNx
or sham-operation. Nephrectomized animals were left untreated or
treated with the ACE inhibitor lisinopril in drinking water. In untreated
UNx animals systolic blood pressure, serum creatinine, urinary protein
and renal synthesis of endothelin-1, evaluated by its urinary excretion,
were significantly increased, as compared with control animals with two
kidneys. End-stage renal failure developed in all untreated UNx rats that
died within 9 to 14 months from UNx. ACE inhibitor significantly reduced
systolic blood pressure, completely prevented proteinuria and renal
function deterioration, and reduced endothelin-1 excretion. All UNx rats
treated with lisinopril were alive 14 months after UNx. These results show
that ACE inhibition prevents end-stage renal failure induced by UNx in
male MWF/Ztm, and that the beneficial effects of angiotensin II inhibition
in this model are related to modulation of renal synthesis of endothelin-1.
In 1985 Anderson and coworkers [1] published the first obser-
vation that angiotensin converting enzyme (ACE) inhibitors re-
duced urinary protein and prevented glomerulosclerosis in a rat
model of progressive nephropathy. Since then an impressive
number of further studies confirmed the reno-protective proper-
ties of this class of compounds in many different experimental
settings, as well as in humans with progressive renal insufficiency
[reviewed in 2, 3]. Of interest, despite the enormous efforts
devoted to confirm the properties of ACE inhibitors to reduce
urinary proteins and glomerular structural abnormalities, there
are virtually no studies addressing whether or not the treatment
prevented or retarded renal insufficiency in animal models.
The mechanisms of the beneficial effect of ACE inhibitors in
retarding renal disease progression has been extensively investi-
gated in the last 10 years, but is not fully clarified yet despite
considerable advances in knowledge. A plausible explanation is
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that ACE inhibitors protect against proteinuria and glomerular
structural abnormalities by selectively reducing efferent arteriolar
resistance, thereby reducing glomerular hypertension [4]. Others
have suggested that ACE inhibitors prevent progressive renal
disease in animal models due to their properties of limiting
angiotensin Il-induced mesangial cell proliferation [5, 61. Since
angiotensin II also induces extracellular matrix protein genes in
mesangial cells [71, the latter has been considered a possible
additional pathway by which ACE inhibitors, by blocking angio-
tensin II activity, may reduce glomerulosclerosis. We provided
experimental evidence that, beside reducing glomerular capillary
pressure, ACE inhibitors have a direct effect on glomerular
membrane function in spontaneous glomerular injury in male
MWF/Ztm rats [8, 9]. Thus, ACE inhibition enhanced hydraulic
permeability and prevented the size-selective defect in glomerular
barrier function by reducing the fraction of large unselective pores
as well as peak pore radius.
A number of other studies have also addressed the effect of
angiotensin II receptor blockade on glomerular barrier function.
In rats with renal ablation that have established proteinuria four
weeks after surgery, angiotensin II blockade significantly reduced
proteinuria by restoring remnant glomerular size-selectivity to
normal [10]. Angiotensin II blockade also protected against renal
injury in experimental diabetes, as documented by amelioration of
glomerular size-selective function in this model [11]. In humans,
converting enzyme inhibitors improved glomerular size-selectivity
in diabetic nephropathy [12, 13] and in IgA nephropathy [14].
So far the favorable effects of ACE inhibitors on renal disease
progression have largely been attributed to their effect of inhib-
iting the biological activity of angiotensin II, and this is supported
by studies that specific inhibitors of angiotensin II receptors share
identical properties. However, there are data that infusion of
angiotensin II sufficient to increase blood pressure and filtration
fraction does not alter membrane pore structure [15]. Recent
evidence is available indicating that angiotensin II modulates the
renal synthesis of endothelin-1 (ET-1), a vasoactive peptide [16]
recently implicated in the process of renal injury [17]. Endothe-
lin-1 secretion by cultured rat mesangial cells was stimulated by
angiotensin II in a concentration-dependent manner [18]. Fur-
thermore, infusion of low and high doses of angiotensin II in the
rat resulted in an enhanced urinary excretion of ET-1 [19], which
likely reflects the renal synthesis of the peptide [20]. Additional
data would suggest that ACE inhibitors interfere with ET-1. Of
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interest, rats with chronic infusion of ET-1, which develop hyper-
tension [211 in the absence of changes in angiotensin II levels,
normalized their blood pressure when given an ACE inhibitor
[221.
The aims of the present study were: (1) to investigate whether
ACE inhibition prevents the development of renal failure in aging
male MWF/Ztm rats subjected to unilateral nephrectomy; and (2)
to study whether in this model the ACE inhibitor interfered with
the generation of ET-1 at a renal level.
Methods
Twenty-one male MWF/Ztm rats, bred and raised in our
facilities, were used in this study. Animals were allowed free
access to food (standard rat chow containing 20% protein by
weight) and water. At nine weeks of age, animals were divided in
three groups, matched for urinary protein excretion, and then
subjected to unilateral nephrectomy (UNx) or sham operation
under ether anesthesia. Five sham operated animals (group 1)
received no treatment during the total observation period. Uni-
nephrectomized animals were divided in two groups: eight rats
were left untreated (group 2), and eight rats were treated with the
ACE inhibitor, lisinopril (Zeneca Pharmaceuticals, Macclesfield,
UK), in the drinking water at the dose of 50 mg/liter throughout
the duration of the study starting one week after nephrectomy
(group 3). At three month intervals systolic blood pressure (SBP)
was recorded by tail plethysmography in awake animals and
24-hour urine collections were obtained using metabolic cages for
determination of protein and ET-1 excretion rate. At the same
time intervals blood samples were collected from the tail vein for
determination of serum creatinine using routine laboratory tech-
nique [23]. Proteinuria was determined by the Coomassie blue
G-dye binding assay with bovine serum albumin as standard [24].
Endothelin-1 concentration in urinary samples was determined
by radioimmunoassay (RIA) as described [20]. Briefly, 10 ml of
24-hour urine samples were applied to a Sep-Pak C18 disposable
column (Waters, Mildford, MA, USA) previously conditioned by
consecutive washing steps with different methanol:water solutions
containing increasing amounts of solvent as described [20]. The
adsorbed peptide was eluted with methanol:water (85:15 vol/vol).
The eluates were liophylized and stored at —20°C until RIA was
performed. Extraction recovery, determined by addition of trace
amounts of '251-ET-1 (2,000 Ci/mmol; Amersham International,
Buckingamshire, UK) to all samples before extraction, was about
80%. The lowest detectable concentration that could be measured
was 0.4 pg/tube. Results are expressed as pg/day. Intra- and
inter-assay variability averaged 9% and 12%, respectively. The
cross-reactivity of the antibody with ET-1 isoforms and validation
of RIA measurement are already reported [201.
Animals were kept in our animal room and followed until
spontaneous death to study the survival time. After spontaneous
death, or under ether anesthesia for control animals with two
kidneys and for treated animals, kidneys were removed and tissue
fragments were immersion-fixed in Dubosq-Brazil fluid and em-
bedded in paraffin. Sections, 3 .tm in thickness, were stained with
Masson's trichrome, hematoxylin and eosin, and by the periodic-
acid Schiff techniques. Sections including superficial and jux-
tamedullary glomeruli were evaluated as previously described
[25]. Briefly, at least 100 glomeruli were examined for each animal
and the percentage of glomeruli affected by focal or global
glomerular sclerosis was determined. Tubular changes (atrophy,
Fig. 1. Periodic measurements of systolic blood pressure in control and in
UNx animals. Values of untreated UNx animals stop at 9 months after
nephrectomy because of spontaneous death. Symbols are: (S) UNx;
(0) control; (0) UNx + Lis. *P < 0.05 vs. Control group at the same time;
< 0.01 vs. Unx and control group at the same time.
casts and dilatation) and interstitial fibrosis and inflammation
were graded from 0 to 4+ (0 — no changes; 1+ = changes
affecting <25% of sample; 2+ = changes affecting 25 to 50% of
sample; 3+ = changes affecting 50 to 75% of sample; 4+ =
changes affecting >75% of sample). Renal biopsies were analyzed
by the same pathologist blind to the nature of the experimental
groups.
All results are expressed as mean SD. Data were analyzed by
two-way analysis of variance and differences between individual
groups assessed by the Tukey-Cicchetti test for multiple compar-
isons [26]. Statistical analysis of estimates of renal damage by
morphological studies were compared with Mann-Whitney test
for non-parametric data. Statistical significance level was defined
as P < 0.05.
Results
Untreated controls and UNx animals (groups 1 and 2) devel-
oped hypertension with age (SBP >140 mm Hg), as reported in
Figure 1, while UNx animals given lisinopril (group 3) were
maintained normotensive during the study period, with values of
SBP never exceeding 130 mm Hg. As shown in Figure 2, untreated
control animals developed spontaneous proteinuria with age that
averaged about 400 mg/24 hrs after 14 months of observation.
Animals of group 2 also developed massive proteinuria with age
(on average 552 117 mg/24 hrs 9 months after UNx). At
variance, UNx animals treated with lisinopril were significantly
protected from proteinuria that averaged only 36 14 mg/24 hrs
at nine months after UNx and then slightly increased (averaging
152 63 mg/24 hrs) by the end of the study. Food intake was
comparable in the three animal groups and body weight, nine
months after nephrectomy, was not significantly different (aver-
aging 477 7, 458 22 and 465 27 g, respectively, in the three
groups). Water diuresis was significantly higher in untreated UNx
animals as compared to both UNx animals treated with lisinopril
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Fig. 2. Urinaty protein excretion rate in control and in UNx animals. Values
of untreated UNx animals stop at 9 months after nephrectomy because of
spontaneous death. Symbols are: (S) UNx; (LI) control; (0) UNx + Lis.
< 0.05 vs. control group at the same time; **p < 0.01 vs. UNx and
control group at the same time; °P < 0.01 vs. Control and UNx + Lis
group at the same time.
and to sham operated controls, values recorded at month nine
averaged respectively 16 2, 34 9 and 24 3 mi/day in groups
1, 2 and 3 (P < 0.01 UNx vs. controls and P < 0.05 UNx vs. UNx
+ lisinopril).
As shown in Figure 3, all control animals with two kidneys
(group 1) were alive 14 months after the sham operation, while all
untreated UNx animals (group 2) died between 9 and 14 months
after nephrectomy. Treatment of UNx animals with the ACE
inhibitor lisinopril (group 3) completely prevented spontaneous
death, so that all animals were alive 14 months after nephrectomy.
At this age animals of groups 1 and 3 were sacrificed to obtain
samples of kidney tissue for morphological evaluation. Untreated
UNx animals (group 2) died because of uremia, as documented by
values of serum creatinine represented in Figure 4. Last values of
serum creatinine measured in this group of animals, as deter-
mined monthly after the ninth month from UNx, averaged 3.46
1.32 g/dl. At variance, animals with two kidneys (group 1) showed
values of serum creatinine always normal, up to 12 months from
sham operation, with a slight tendency to increase at 14 months,
at which time serum creatinine averaged 1.21 0.30 gldl. UNx
animals treated with lisinopril (group 3) did not develop renal
failure and showed stable values of serum creatinine during the
entire duration of the study (14 months after UNx serum creati-
nine averaged 1.02 0.07 gIdl). Kidney weight was significantly
higher in UNx animals than in sham operated controls (1.84
0.22 vs. 1.43 0.06 g, P < 0.01). In UNx animals treated with
lisinopril kidney weight averaged 1.65 0.13 g, a value not
significantly different from both groups 1 and 2.
The results of the morphological evaluation are reported in
Figure 5 and 6. As previously reported [8, 25], control male
MWF/Ztm rats with two kidneys (group 1) developed important
glomerular lesions spontaneously with age, affecting on average
69% (range 46 to 87%) of glomentli. Also interstitial nephrosis
(mean score 2.6) and tubular damage (mean score 2.6) were
present in these animals. Untreated UNx animals developed more
severe renal damage. Glomerulosclerosis incidence averaged 94%
(range 89 to 98%) with 13.5% of glomeruli on average affected by
global sclerosis. Both interstitial nephrosis and tubular damage
had a mean score of 3.7 in these animals. At variance, treatment
with lisinopril importantly prevented damage of glomerular and
tubular structure. In animals of group 3 glomeruli affected by
sclerosis were only 9.1% (range 4 to 18%) with none of them
showing global sclerosis. Interstitial nephrosis and tubular dam-
age were minor in these kidneys (score average 1.0 for both).
Thus, glomerular and tubular structure were significantly pro-
tected, not only in comparison with UNx animals left untreated,
but also with control animals with two kidneys.
Urinary ET-1 excretion values for the three groups of animals
are reported in Figure 7. In sham-operated animals ET-1 excre-
tion was almost constant during the observation period, with
average values ranging from 46 to 70 pg/24 hrs. Three months
after nephrectomy, ET-1 excretion increased in animals of group
2 (116 47 pg/24 hrs) in respect to sham-operated controls,
although statistical significance was not reached. Urinary ET-1
excretion values became significantly (P < 0.01) different from
sham operated controls starting from six months after the surgical
procedure. At this time, ET-1 excretion averaged 210 56 pg/24
hrs. Urinary ET-1 values remained constantly elevated (185 75
pg/24 hrs, P < 0.01) over sham-operated animals at nine months
after nephrectomy. The last value of urinary ET-1 excretion,
measured in animals of group 2 between 10 and 12 months after
nephrectomy, further increased with time averaging 430 102
pg/24 hrs (data not shown in Fig. 7). Lisinopril treatment signif-
icantly (P < 0.01) reduced the increase in ET-1 excretion induced
by UNx at all time points evaluated. As compared to control
animals with two kidneys urinary ET-1 excretion in lisinopril
treated animals was significantly reduced at three months after
nephrectomy (44 15 vs. 70 10 pg/24 hrs, P < 0.05). In
contrast, in animals given lisinopril urinary ET-1 was significantly
higher than controls at 6 and 9 months after the surgical proce-
dure (6 months, 110 13 vs. 46 5 pg/24 hrs; 9 months, 88 13
vs. 52 5 pg/24 hrs, P < 0.05). By the end of the observation
period (14 months from UNx) animals treated with lisinopril
showed ET-1 excretion values comparable to those measured in
control rats with two kidneys (47 10 vs. 61 6 pg/24 hrs).
Discussion
We have documented that the ACE inhibitor, lisinopril, effec-
tively reduced systemic blood pressure in aging male MWF/Ztm
rats. Actually at variance with untreated control and UNx animals,
values of SBP were normal in UNx rats on lisinopril during the
whole study period. Urinary protein excretion values were also
significantly lower at all observation times in UNx animals on
lisinopril as compared to untreated UNx and normal controls. The
effect of lisinopril of restoring glomerular permeability properties
in this model was associated with a remarkable effect of limiting
glomerular structural injury as reflected by significantly less
glomerulosclerosis and tubulointerstitial injury in animals treated
with lisinopril as compared to untreated nephrectomized rats and
normal controls. Renal pathology data were totally unexpected
and quite remarkable. Actually the effect of lisinopril on signs of
renal injury was such that UNx animals had also fewer lesions
than age-matched controls with two kidneys and the differences
were very impressive (Fig. 5). The major finding of the current
0 3 6 9 12 15
Time, months after UNx
Fig. 4. Periodic measurements of serum creatinine in control and UNx
animals. Lines represent time course of serum creatinine in individual
animals. In untreated UNx animals crosses represent last values measured
before animal death (group 1). Symbols are: ( ) control; ( x)
Unx; ( ) UNx + Lis.
study, however, is that end..stage renal failure and death, that
invariably developed in UNx animals 10 to 14 months after
surgery, were completely prevented by lisinopril. Finally, we found
that lisinopril also significantly reduced the elevated values of
urinary ET-1 that followed UNx.
To our knowledge this is the first demonstration that ACE
inhibition, besides ameliorating glomerular membrane selectivity
and reducing glomerular injury, protects animals from progressive
renal failure and death. Thus, the current results rise the question
of whether ACE inhibition represents the best possible approach
to limit the evolution of human nephropathies to renal failure. So
far the most convincing human study of this kind is the one of
Lewis and coworkers 27J that indeed shows that captopril re-
tarded the rate of loss of renal function in the progressive
nephropathy associated with type I diabetes. Quite consistent with
Fig. 3. Survival curve of control, untreated UNx
and lisinopril-treated UNx animals. All control
rats (group 1) and lisinopril-treated UNx rats
(group 3) were alive at the end of the
observation period. All untreated UNx animals
(group 2) died before 14 months after
nephrectomy.
Fig. 5. Percentage of glomendi affected by sclerosis in control and UNx
animals by the end of the observation period. Bars represent the total
percentage of glomeruli affected by sclerosis while black areas represent
the percentage of glomeruli affected by global sclerosis. In UNx animals
treated with lisinopril glomeruli affected by global sclerosis were not
observed.
the present animal data the above study in diabetic patients also
documented that captopril did significantly decrease the com-
bined risk of renal failure and death. Data on the protective effect
of the ACE inhibition on renal function deterioration in diabetic
humans of the above trial were in line with the results of small,
short-term studies published previously [28, 291.
Whether the renal effect of drugs that reduce systemic blood
pressure in animal and human nephropathies is simply the
consequence of blood pressure lowering effect or is due to some
local effect not necessarily related to systemic blood pressure is
one of the most debated issue in the renal literature these days. In
the Lewis's study the effects of captopril of limiting diabetic renal
disease progression appeared independent of its antihypertensive
effect. In a recent study from our group the calcium channel
blocker nitrendipine, despite an effect on systemic blood pressure
UNx + Lis
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Fig. 6. Representative light micrographs at low (X100) and medium (X400) power magnification of glomeruli from control (group 1, A and B), untreated
UNx (group 2, C and D) and lisinopril-treated UNx animals (group 3, E and F). Paraffin sections, 3 urn thick were stained with Masson's thrichrorne.
'I};
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Fig. 7. Time course of urina,y ezcretion rate of ET-1 in unilateral nephrec-
tomized rats given lisinopril (E, UNx + lis) or no treatment (0, UNx,) and
in sham operated animals (, control). P < 0.01 vs. UNx and P < 0.05 vs.
control at the same time; *D < 0.01 vs. control at the same time.
control comparable to that of the ACE inhibitor lisinopril, did not
protect animals against proteinuria and glomerular lesions [9].
This, however, remains a controversial issue given the fact that
other animal and human studies [30, 31] did indeed find a
protective effect of calcium channel blockers which is generally
less effective than ACE. inhibition.
Experimental and human data are available which consistently
document that the protective effect of ACE inhibition on renal
function deterioration is always associated with a remarkably
improved glomerular barrier permeability to proteins [8, 12, 141.
We and others [10, 11] have previously demonstrated that block-
ing renin-angiotensin system by converting enzyme inhibitors or
angiotensin II antagonists reduces to normal the number and
dimension of large unselective pores that form within the glomer-
ular barrier in proteinuric renal diseases. This could be taken as
an indication that reducing angiotensin II serves to repair the
selectivity of the barrier. Of interest, remarkably similar results
have been obtained both in animal and human studies, suggesting
that this effect is not confined to a given model but is likely a
generalized phenomenon. Our present data further stress the
possibility that, on the long term, restoring size-selective and
hydraulic permeability functions limit the renal evolution of the
disease to uremia. Within the limit of the assumption that ACE
inhibitors are better reno-protective than other antihypertensives
by virtue of their unique property of improving the permeability of
the glomerular membrane to macromolecules and water, it is
logical to think to a direct effect on the structural/functional
properties of the membrane. This is consistent with very recent
findings that the ACE inhibitor enalapril modulates extracellular
matrix protein composition [321.
Another interesting finding of the current study is that, despite
the fact that male MWF/Ztm rats do develop glomerular damage,
this was not associated with renal failure unless uninephrectomy
was also performed. Thus the current study is a major support to
the view that fewer nephrons, particularly in the presence of a
pre-existing renal disease, initiates a program of glomerular and
tubulointerstitial events that eventually trigger progression of the
disease to renal failure [33]. This is exemplified by the extreme
condition of oligomeganephronia—a disease of congenital reduc-
tion in the number of glomeruli—that after a period of compen-
satory hyperfiltration evolves toward overt proteinuria and renal
insufficiency [34, 35].
We have previously reported that in rats with progressive renal
disease triggered by extensive renal mass ablation urinary ET-1
increases progressively with time and parallels the severity of
renal injury [20]. Moreover, renal prepro-ET-1 gene expression
increases in these animals [36]. Exaggerated formation of ET-1 in
the kidney in a more general way characterizes the development
of progressive nephropathies, as documented by subsequent data
in other models of disease progression including remnant kidney,
immunological nephritis and streptozotocin diabetes [20, 37, 38].
In vitro ET-1 mRNA levels in glomeruli of diabetic rats increased
with the progression of diabetic nephropathy [38]. These latter
findings are consistent with data from our group [20] and from
others [391 that enhanced ET-1 urinary excretion values reflect an
enhanced renal synthesis of the peptide rather than events in the
systemic circulation. In the current study we found that chronic
renal failure in UNx male MWF/Ztm rats was also associated with
an increased urinary ET-1. Endothelin-1, beside its potent effect
of reducing renal blood flow, induces mesangial cell proliferation
[40] and stimulates extracellular matrix synthesis [41]. That ET-1
may be a potential mediator of damage in progressive renal
disease rests on data that a specific endothelin subtype A receptor
antagonist, given to rats with reduction of renal mass, ameliorated
proteinuria, limited glomerular injury and prevented renal func-
tion deterioration [42]. In the current study we found that
lisinopril significantly reduced urinary excretion of ET-1 as com-
pared to untreated nephrectomized animals. However, the reduc-
tion in injury seen with in the ACE inhibitor group far exceeded
the observed reduction in ET-1 excretion. Specifically, in animals
treated with lisinopril proteinuria and sclerosis were almost
completely prevented and showed ET-1 excretion values higher
than in normal controls, and, on the other hand, despite low ET-1
excretion sham operated controls developed massive proteinuria
and glomerular sclerosis. Altogether the above observations
would indicate that in this setting, the effect of lisinopril in
preventing renal failure and death may not simply derive from its
property of lowering ET-l, but other mediators must be involved
[43].
The mechanism of the specific suppressing effect of the ACE
inhibitor on renal ET-1 formation must remain speculative at the
moment. Since in another study [44] captopril-induced suppres-
sion of ET-1 formation did not correlate with the fall in blood
pressure, there are reasons to believe that factors other than
angiotensin II inhibition explain the effect of ACE inhibitors on
ET-1. In cultured endothelial cells bradykinin is a potent inhibitor
of ET-1 synthesis, and ACE inhibitor inhibits ET-1 secretion by
the accumulation of endogenous bradykinin [45]. These data
would suggest that drug-induced potentiation of bradykinin might
account for the effect of lisinopril on urinary ET-1 observed in the
present study. Alternatively, ACE inhibitors may normalize renal
ET-1 by enhancing endothelial cGMP, a phenomenon that likely
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depends on endothelial nitric oxide synthesis, also promoted by
the accumulation of bradykinin {46j.
In conclusion, our present data indicate that ACE inhibition
effectively prevents kidney structural and functional damage
which develops in male MWF/Ztm rats after unilateral nephrec-
tomy leading to end-stage renal failure. The impressive effect of
the ACE inhibition in this model of renal failure should stimulate
extensive investigation on the possibility that this treatment
prevents the progression of proteinuric renal diseases to end-stage
renal failure in humans.
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